Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Jan 18;7(2):225–232. doi: 10.1002/jcsm.12054

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2016 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of the Society of Sarcopenia, Cachexia and Wasting Disorders

This is an open access article under the terms of the Creative Commons Attribution‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited and no modifications or adaptations are made.

PMC Copyright notice

Therapeutic efficacy of salidroside in the model of cachexia induced by CT‐26. Cachexia was induced in BABL/c mice by subcutaneous injection of CT‐26 cells, which were characterized by obvious decreases of body weight and food intake and significant loss of gastrocnemius muscle and fat mass compared with the negative control. Tumour‐bearing mice were treated with NS, salidroside (60 mg/kg/day), and salidroside (120 mg/kg/day), respectively. Effects of salidroside on the main features of cachexia were examined, including (B) tumour growth, (C) body weight, (D) tumour‐free body weight, (E) gastrocnemius muscle, (A) fat mass (bottom, epididymal WAT; top panel, gonadal WAT), (F) food intake, and (G) survival. Data were presented as mean ± SEM (*P < 0.05, **P < 0.01, ***P < 0.001). WAT, white adipose tissue. Negative, the healthy BABL/c mice.